ArticleEuropean journal of nuclear medicine and molecular imaging2024
Preclinical study and first-in-human imaging of [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Revolutionizing cancer diagnosis and dose biodistribution: a meta-analysis of [68ga] FAPI- 46 vs. [18f] FDG imaging.Systematic reviews · 2025Pooled it
- Head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- The Current Status of Radionuclide Tumor Targeting Diagnosis and Therapy Based on FAP-2286: From Preclinical Studies to Clinical Application.Molecular diagnosis & therapy · 2026Review
- The comparative diagnostic and therapeutic application value of FAPI PET/CT andFrontiers in oncology · 2026Review
- Fibroblast activation Protein-Targeted PET/CT using [18 F]FAP-2286 for the evaluation of lung cancer: A comparative study with [18 F]FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- Clinical comprehensive evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Preclinical evaluation of [Scientific reports · 2025Article
- Design, Synthesis, and Biological Evaluation of a Novel [Pharmaceuticals (Basel, Switzerland) · 2025Article
- Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025Review
- Review
- [European journal of nuclear medicine and molecular imaging · 2024Article
- Preclinical evaluation and first-in-human study of [EJNMMI research · 2024Article
- Article
- Radiolabelled FGF-2 for Imaging Activated Fibroblasts in the Tumor Micro-Environment.Biomolecules · 2024Article
- Comparison ofFrontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeFibroblast-activated protein (FAP) is highly expressed in cancer-associated fibroblasts (CAFs) of many solid cancers, but low or absent in normal tissues. Our study aimed to develop a novel FAP-specific tracer, namely [
methods[
resultsThe radiolabeling yield of [
conclusion[
Indexed as
Identifiers
38326656What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.